Core Viewpoint - Kestra Medical Technologies, Ltd. announced an underwritten public offering of 5,500,000 common shares to support various corporate activities including sales, marketing, research, and working capital [1] Group 1: Offering Details - The offering is made under a registration statement filed with the SEC and includes a 30-day option for underwriters to purchase an additional 825,000 shares [1] - The offering is subject to market conditions and there are no guarantees regarding its completion or terms [1] - The proposed offering will be conducted only through a prospectus, with preliminary copies available from designated financial institutions [2][3] Group 2: Company Overview - Kestra Medical Technologies focuses on wearable medical devices and digital healthcare, aiming to improve patient outcomes in cardiovascular disease through innovative monitoring and therapeutic technologies [6]

Core Viewpoint - Pasithea Therapeutics Corp. has announced a public offering of 80 million shares at $0.75 per share, aiming to raise approximately $60 million to support its ongoing research and development efforts [1][3]. Group 1: Offering Details - The public offering consists of 80,000,000 shares of common stock or pre-funded warrants at an offering price of $0.75 per share [1]. - The offering is led by healthcare-focused investors, including Vivo Capital, Janus Henderson Investors, and others [1][8]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2]. Group 2: Financial Implications - The gross proceeds from the offering are expected to be around $60 million before deducting fees and expenses [3]. - The net proceeds will be used for general corporate purposes, including ongoing research, clinical trials, and potential acquisitions [3]. - Following the offering, the company's cash runway is projected to extend through at least the first half of 2028 [3][8]. Group 3: Company Overview - Pasithea is a clinical-stage biotechnology company focused on developing PAS-004, a macrocyclic MEK inhibitor for treating neurofibromatosis type 1-associated plexiform neurofibromas [6]. - The company is currently conducting a Phase 1 clinical trial for PAS-004 in advanced cancer patients and a Phase 1/1b trial in adult patients with NF1-associated plexiform neurofibromas [6].

Core Viewpoint - Shares of Fannie Mae experienced significant volatility last week, influenced by investor Bill Ackman's presentation, which did not provide clarity on the anticipated public offering [1] Group 1 - Fannie Mae's stock performance has been erratic, reflecting uncertainty in the market regarding its future [1] - Bill Ackman, a prominent investor, presented insights that failed to alleviate concerns about the planned public offering [1]

Core Viewpoint - GoGold Resources Inc. has filed a final short form prospectus for a C$125 million bought deal public offering, consisting of 47,170,000 units priced at C$2.65 each, with each unit comprising one common share and half a warrant [1][2]. Group 1: Offering Details - The offering includes an over-allotment option allowing underwriters to purchase up to an additional 15% of the offering within 30 days of closing [2]. - The closing of the offering is expected around November 27, 2025, with conditional approval from the Toronto Stock Exchange [3]. Group 2: Company Overview - GoGold Resources is a Canadian-based silver and gold producer focused on high-quality projects in Mexico, including the Parral Tailings mine and the Los Ricos exploration projects [6]. - The company aims to build a portfolio of low-cost, high-margin projects [6].

Core Insights - Bill Ackman is planning to take his hedge-fund management company, Pershing Square, public alongside a new investment entity, with a potential double public offering as early as next year [1][2] - The new fund, Pershing Square USA, aims to attract investors by offering free shares of Pershing Square, with partners willing to give away up to 10% of their shares [2] - Preliminary discussions regarding the public listing of Pershing Square have begun, with potential plans for the first quarter of 2026, although these talks are still in early stages and may change based on market conditions [3] Company Overview - Pershing Square USA is designed as a closed-end fund, which means it will sell a fixed number of shares in a public offering, and shareholders can only exit by selling their stakes at market price [4] - The initial prospectus for Pershing Square USA was filed in early 2024, but the IPO was withdrawn in July of that year due to insufficient investor interest, leading to a reduction in size from $25 billion to $2 billion [4] - Founded in 2004, Pershing Square has transitioned from an activist hedge fund to focusing on concentrated stakes in large public companies, currently managing over $21.4 billion in core assets as of October [5] Recent Developments - Pershing Square has recently acquired nearly half of Howard Hughes Holdings, with Ackman expressing ambitions to transform it into "a modern-day Berkshire Hathaway" [6]

Core Viewpoint - Conavi Medical Corp. has filed a preliminary short form prospectus for an offering of common shares and/or pre-funded common share purchase warrants to support the launch of its Novasight Hybrid system and for general corporate purposes [2][4]. Offering Details - The offering will be conducted on a commercially reasonable efforts agency basis through Bloom Burton Securities Inc. [3] - The final terms, including the number of securities and pricing, will be determined through negotiations between the company and the agent [3]. - The expected closing date for the offering is around December 12, 2025, subject to customary closing conditions and regulatory approvals [5]. Use of Proceeds - The net proceeds from the offering will be utilized to obtain US FDA 510(k) clearance for the Novasight Hybrid system, complete a limited market release, and initiate a broader commercial launch in the United States [4]. Company Overview - Conavi Medical focuses on designing, manufacturing, and marketing imaging technologies for minimally invasive cardiovascular procedures [9]. - The Novasight Hybrid™ System combines intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device, allowing simultaneous imaging of coronary arteries [9][10].

Core Viewpoint - Inhibikase Therapeutics, Inc. has announced a public offering of common stock and pre-funded warrants to raise approximately $100 million to support its development of therapeutics for pulmonary arterial hypertension (PAH) [1][5] Group 1: Offering Details - The company is offering 46,091,739 shares of common stock at a price of $1.45 per share and pre-funded warrants at $1.449 each, with a total expected gross proceeds of around $100 million before expenses [1] - An additional 10,344,827 shares may be purchased by underwriters within 30 days at the public offering price [1] - The offering is expected to close on November 24, 2025, subject to customary closing conditions [1] Group 2: Underwriters - Jefferies, BofA Securities, and Cantor are acting as joint book-running managers for the offering [2] - LifeSci Capital and Oppenheimer & Co. are co-lead managers, while H.C. Wainwright & Co. and Ladenburg Thalmann & Co. Inc. are co-managers [2] Group 3: Company Overview - Inhibikase Therapeutics is focused on developing therapeutics for cardiopulmonary diseases, particularly PAH, which affects approximately 50,000 Americans [5] - The lead product candidate is IKT-001, a prodrug of imatinib mesylate, targeting the underlying mechanisms of PAH [5]

Core Points - Olema Pharmaceuticals, Inc. has announced a public offering of 10,000,000 shares of its common stock priced at $19.00 per share [1] - The gross proceeds from the offering are expected to be approximately $190.0 million before deductions [2] - The offering is expected to close on November 20, 2025, subject to customary closing conditions [2] Company Overview - Olema Oncology is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other conditions [1] - The company is advancing a pipeline of novel therapies, including its lead product candidate, palazestrant (OP-1250), which is currently in two Phase 3 clinical trials [6] - Olema is also developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, which is in a Phase 1 clinical study [6]

Company Overview - Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other conditions [1][5] - The company is advancing a pipeline of novel therapies, including its lead product candidate, palazestrant (OP-1250), which is currently in two Phase 3 clinical trials [5] Public Offering Announcement - Olema announced plans to commence a public offering of its common stock, which may include pre-funded warrants for certain investors [1] - The offering is subject to market conditions and will be managed by TD Cowen as the book-running manager [2] Offering Details - The proposed offering includes a 30-day option for underwriters to purchase up to an additional 15% of the total number of shares being offered [2] - The offering is made pursuant to a shelf registration statement filed with the SEC on January 6, 2025, and declared effective on January 15, 2025 [3]

Core Viewpoint - Apyx Medical Corporation has announced a public offering of 2,762,431 shares of its common stock at a price of $3.62 per share, with the offering expected to close on or about November 19, 2025 [1][2]. Group 1: Offering Details - The offering is underwritten by Lucid Capital Markets, which is acting as the sole book-running manager [2]. - The company has granted the underwriter a 45-day option to purchase an additional 414,365 shares at the public offering price [2]. - The net proceeds from the offering will be used for working capital and general corporate purposes [3]. Group 2: Regulatory and Documentation - The offering is made pursuant to a shelf registration statement filed with the SEC, which was declared effective on December 2, 2022 [3]. - A preliminary prospectus supplement and accompanying prospectus have been filed with the SEC and are available on their website [4]. Group 3: Company Overview - Apyx Medical Corporation specializes in surgical aesthetics, offering products like Renuvion and the AYON Body Contouring System, which provide innovative solutions in cosmetic surgery [6]. - The company’s technologies, including Helium Plasma Platform Technology, are supported by over 90 clinical documents, demonstrating their effectiveness [6]. - The AYON Body Contouring System is FDA-cleared and designed to integrate multiple surgical capabilities, enhancing the treatment options available to surgeons [6].